Consider Cardiovascular Benefits When Choosing a GLP-1 Agonist
August 2019
Trulicity (dulaglutide) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.
It joins Ozempic (semaglutide) and Victoza (liraglutide). All three lower CV risk in type 2 patients with CV disease or at high CV risk.
Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote